Jiangsu Chinagreen Biological Technology Group Co.,Ltd. (SHE:300970)
China · Delayed Price · Currency is CNY 23.20
+0.44 (1.93%)
Feb 12, 2026, 4:00 PM EST
SHE:300970 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,164 | 1,032 | 996.22 | 751.58 | 578.08 | 609.4 |
Other Revenue | - | - | - | 0.02 | 0 | - |
| 1,164 | 1,032 | 996.22 | 751.59 | 578.09 | 609.4 | |
Revenue Growth (YoY) | 18.72% | 3.60% | 32.55% | 30.01% | -5.14% | 5.90% |
Cost of Revenue | 1,074 | 982.52 | 870.12 | 632.47 | 539.94 | 443.45 |
Gross Profit | 90.32 | 49.59 | 126.1 | 119.12 | 38.15 | 165.95 |
Selling, General & Admin | 69.53 | 78.37 | 80.18 | 49.29 | 37.25 | 33.37 |
Research & Development | 14.2 | 14.61 | 16.53 | 14.04 | 8.62 | 8.82 |
Other Operating Expenses | -8.35 | -8.14 | -7.91 | 0.53 | 0.41 | 0.35 |
Operating Expenses | 75.99 | 86.44 | 89.32 | 64.29 | 46.72 | 42.41 |
Operating Income | 14.33 | -36.85 | 36.78 | 54.83 | -8.58 | 123.54 |
Interest Expense | -17.16 | -11.18 | -8.75 | -2.69 | -3.83 | -6.77 |
Interest & Investment Income | 5.74 | 3.37 | 9.18 | 16.7 | 16.21 | 7.1 |
Currency Exchange Gain (Loss) | - | - | - | - | 0 | -0 |
Other Non Operating Income (Expenses) | 0.33 | 0.27 | 1.8 | -0.39 | -0.2 | 0.17 |
EBT Excluding Unusual Items | 3.23 | -44.4 | 39.01 | 68.44 | 3.6 | 124.04 |
Gain (Loss) on Sale of Investments | - | - | -0.17 | -0.06 | 0.24 | 0.03 |
Gain (Loss) on Sale of Assets | -1.74 | -1.48 | -10.89 | -1.33 | -0.26 | -0.01 |
Asset Writedown | 2.45 | -1 | -3.57 | -0.36 | - | -0 |
Other Unusual Items | 2.55 | 2.6 | 2 | 13.29 | 13.21 | 8.3 |
Pretax Income | 6.49 | -44.28 | 26.37 | 79.99 | 16.79 | 132.36 |
Income Tax Expense | 0.04 | 0.15 | 0 | 2.32 | 0.51 | 0.15 |
Earnings From Continuing Operations | 6.46 | -44.42 | 26.37 | 77.67 | 16.28 | 132.21 |
Minority Interest in Earnings | -2.6 | -3.14 | 3.98 | 0.59 | -0.78 | 0.29 |
Net Income | 3.86 | -47.57 | 30.35 | 78.25 | 15.5 | 132.5 |
Net Income to Common | 3.86 | -47.57 | 30.35 | 78.25 | 15.5 | 132.5 |
Net Income Growth | - | - | -61.22% | 404.70% | -88.30% | 9.80% |
Shares Outstanding (Basic) | 117 | 116 | 117 | 117 | 111 | 102 |
Shares Outstanding (Diluted) | 117 | 116 | 117 | 117 | 111 | 102 |
Shares Change (YoY) | 0.74% | -0.61% | -0.06% | 5.46% | 8.66% | 16.56% |
EPS (Basic) | 0.03 | -0.41 | 0.26 | 0.67 | 0.14 | 1.30 |
EPS (Diluted) | 0.03 | -0.41 | 0.26 | 0.67 | 0.14 | 1.30 |
EPS Growth | - | - | -61.19% | 378.57% | -89.23% | -5.80% |
Free Cash Flow | 97.83 | -130.42 | -57.48 | -228.07 | -121.01 | 8.13 |
Free Cash Flow Per Share | 0.83 | -1.12 | -0.49 | -1.95 | -1.09 | 0.08 |
Dividend Per Share | - | - | 0.200 | 0.200 | - | 0.260 |
Dividend Growth | - | - | - | - | - | 4.00% |
Gross Margin | 7.76% | 4.81% | 12.66% | 15.85% | 6.60% | 27.23% |
Operating Margin | 1.23% | -3.57% | 3.69% | 7.29% | -1.48% | 20.27% |
Profit Margin | 0.33% | -4.61% | 3.05% | 10.41% | 2.68% | 21.74% |
Free Cash Flow Margin | 8.40% | -12.64% | -5.77% | -30.34% | -20.93% | 1.33% |
EBITDA | 171.97 | 103.61 | 154.31 | 151.79 | 75.92 | 199.64 |
EBITDA Margin | 14.77% | 10.04% | 15.49% | 20.20% | 13.13% | 32.76% |
D&A For EBITDA | 157.64 | 140.45 | 117.53 | 96.96 | 84.49 | 76.09 |
EBIT | 14.33 | -36.85 | 36.78 | 54.83 | -8.58 | 123.54 |
EBIT Margin | 1.23% | -3.57% | 3.69% | 7.29% | -1.48% | 20.27% |
Effective Tax Rate | 0.59% | - | - | 2.90% | 3.02% | 0.11% |
Revenue as Reported | 1,164 | 1,032 | 996.22 | 751.59 | 578.09 | 609.4 |
Advertising Expenses | - | 0.45 | 0.26 | 0.03 | 0.89 | 0.52 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.